TARGETING PROGRAMMED CELL DEATH-1 (PD-1)

• In: A7 - Cancer immunotherapy: using drugs and cells to exploit our immune systems on Friday, 2 October 2015, 09:00-12:00
• At: Düsseldorf (Germany) (2015)
• Type: Presentation
• By: HARVEY, R. Donald (Winship Cancer Institute of Emory University, Hematology/Medical Oncology, Avondale Estates, United States)
• Co-author(s): R. Donald Harvey
  
• Abstract:

  Therapeutic antibodies that block the programmed cell death protein-1 (PD-1) immune checkpoint pathway prevent T-cell downregulation and promote immune responses against a number of cancer types. The US FDA has approved pembrolizumab for the treatment of advanced melanoma and nivolumab for advanced melanoma and squamous cell non-small cell lung

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login